Pyrazinamide
Pyrazinamide, Rifater (pyrazinamide) is a small molecule pharmaceutical. Pyrazinamide was first approved as Pyrazinamide on 1982-01-01. It is used to treat mycobacterium infections and tuberculosis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Pyrazinamide
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pyrazinamide | ANDA | 2024-10-16 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AK: Other drugs for treatment of tuberculosis in atc
— J04AK01: Pyrazinamide
— J04AM: Combinations of drugs for treatment of tuberculosis
— J04AM05: Rifampicin, pyrazinamide and isoniazid
— J04AM06: Rifampicin, pyrazinamide, ethambutol and isoniazid
HCPCS
No data
Clinical
Clinical Trials
211 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 16 | 78 | 41 | 21 | 31 | 171 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 5 | 44 | 22 | 6 | 8 | 75 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 6 | 9 | 5 | 7 | 27 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 8 | 8 | 5 | 5 | 24 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 1 | — | 1 | 2 | 4 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 1 | — | 1 | — | 2 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 1 | 1 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | 1 | 2 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | 2 | — | 2 |
| Conduct disorder | D019955 | EFO_0004216 | F91 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 2 | 6 | — | 4 | 12 |
| Meningeal tuberculosis | D014390 | — | A17.0 | 1 | 8 | 3 | — | — | 10 |
| Meningitis | D008581 | HP_0001287 | G03 | — | 7 | 3 | — | — | 9 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | 1 | — | 3 | — | 2 | 6 |
| Hiv | D006678 | — | — | 1 | 2 | 2 | — | 1 | 6 |
| Infections | D007239 | EFO_0000544 | — | — | — | 3 | — | 2 | 5 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 4 | 2 | — | — | 5 |
| Uveitis | D014605 | HP_0000554 | H20.9 | — | 1 | 1 | — | 1 | 3 |
| Communicable diseases | D003141 | — | — | — | — | 1 | — | 2 | 3 |
| Coinfection | D060085 | — | — | — | 1 | 1 | — | 1 | 3 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | 2 | — | — | 1 | 3 |
| Pharmacokinetics | D010599 | — | — | 1 | 1 | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | — | — | 1 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | 1 | 2 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | — | — | — | 1 |
| Hepatitis c | D006526 | — | B19.2 | — | 1 | — | — | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
| Pharmacological phenomena | D000069437 | — | — | — | 1 | — | — | — | 1 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | — | — | — | — | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Magnetic resonance imaging | D008279 | — | — | 1 | — | — | — | — | 1 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | — | — | — | — | 1 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 3 | 3 |
| Ocular hypotension | D015814 | — | H44.4 | — | — | — | — | 1 | 1 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | — | — | — | 1 | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | — | 1 | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pyrazinamide |
| INN | pyrazinamide |
| Description | Pyrazinecarboxamide is a monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis. It has a role as an antitubercular agent and a prodrug. It is a member of pyrazines, a N-acylammonia and a monocarboxylic acid amide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1cnccn1 |
Identifiers
| PDB | — |
| CAS-ID | 98-96-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL614 |
| ChEBI ID | 45285 |
| PubChem CID | 1046 |
| DrugBank | DB00339 |
| UNII ID | 2KNI5N06TI (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Pyrazinamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 30,447 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,677 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use